Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)

28 Jan 20264 min read0 viewsJournal Feed

GIST

Journal of Clinical Oncology, Volume 44, Issue 12 , Page 1083-1097, April 2026.

Clinical Editorial

Summary

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 28 Jan 2026. The item focuses on Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII). Open the detail page to review the full original feed content.